Gabapentin 300 mg Capsules: Neurontin and Generic Product Guide

Gabapentin 300 mg capsules are prescription products in the United States. Neurontin is the branded gabapentin product, while many approved generic gabapentin capsules are marketed under ANDAs by different manufacturers and labelers.

Neurontin and generic gabapentin

The active ingredient is gabapentin. Current Neurontin labeling identifies 300 mg capsules as one of the branded dosage forms and lists the product as prescription only. Current generic labels also include 300 mg capsules. DailyMed records in 2026 show multiple generic products under different ANDAs, including products or repackaged products sourced from ScieGen, Strides and other manufacturers.

This makes the exact product identity important for anyone comparing packages. “Gabapentin 300 mg” describes an active ingredient, strength and dosage form, but not one single tablet or capsule appearance. Generic capsules can differ in color, imprint, shell ingredients, bottle size and NDC.

What the 300 mg capsule is — and is not

A 300 mg capsule is not interchangeable with every gabapentin dosage form solely because the active ingredient is the same. Gabapentin is marketed in multiple capsule strengths and other dosage forms. Product comparison should therefore include the dosage form as well as the strength.

The current generic DailyMed labels identify gabapentin capsules as human prescription drugs. Some current labels list “DEA Schedule: None.” That is a statement about federal scheduling in the referenced drug label, not a claim that every state treats gabapentin identically for monitoring or controlled-substance purposes. State requirements can differ and may change. Federal scheduling should therefore not be generalized into a claim that every state applies identical rules.

Current labeled uses

Current U.S. gabapentin capsule labeling includes postherpetic neuralgia in adults and adjunctive therapy for partial-onset seizures in adults and pediatric patients of specified ages. Gabapentin is also discussed in many other clinical contexts, but a use mentioned online is not automatically an FDA-approved indication.

Product research should be separated from dosing advice. Starting, stopping, tapering or changing gabapentin requires prescriber guidance. Abrupt changes can be clinically important, particularly for patients using it for seizure-related indications.

Manufacturer and refill differences

A patient who receives a different-looking 300 mg capsule should check the prescription label, imprint and manufacturer with the pharmacy. For example, one 2026 DailyMed listing describes a 300 mg generic capsule with imprint SG 180, while other approved products use different imprints and colors. These differences can reflect different approved manufacturers rather than a difference in prescribed strength.

Insurance formularies and wholesaler supply can also affect which generic is dispensed. If a patient has a documented reason to avoid a particular inactive ingredient or needs consistency with a specific manufacturer, that should be discussed with the pharmacist before the prescription is filled.

Access and cost questions

Useful pre-purchase questions include whether the prescription is specifically for capsules, which manufacturer or NDC is expected, whether the insurer applies quantity limits or other utilization rules, and whether the quoted amount is a copay or cash price. A generic product’s price can change with supplier, plan and quantity.

Contact the pharmacy to confirm current availability, product identity and coverage for a specific prescription.

Federal scheduling and state rules are different concepts

Gabapentin is a good example of why regulatory language needs precision. Current DailyMed labels for gabapentin capsules may show “DEA Schedule: None,” reflecting that the product is not scheduled under the federal Controlled Substances Act in those records. That statement should not be expanded into “gabapentin is uncontrolled everywhere.” States can create additional prescription-monitoring or controlled-substance requirements independent of federal scheduling.

For a California pharmacy customer, the practical question is what current federal and California dispensing rules require at the time the prescription is filled. Because those rules can change, current requirements should be checked when the prescription is dispensed.

Brand, generic and repackaged products

DailyMed also distinguishes manufacturers from repackagers. A package may carry a repackager’s NDC while identifying a source NDC from the underlying manufacturer. That is not the same as a new active ingredient or strength. It is one reason a patient can see different company names associated with gabapentin 300 mg.

When comparing products, it is useful to ask the pharmacy which manufacturer produced the capsule and whether the pharmacy label reflects a repackaged NDC. The pharmacist can then reconcile the imprint, source product and strength if a capsule looks unfamiliar.

Online listings are not a substitute for a U.S. product label

For gabapentin 300 mg, a U.S. DailyMed label provides a much stronger identity check than an anonymous marketplace photograph. The label links the strength and dosage form to an NDC, approval pathway and responsible company.

For broader patient-facing information, see Medication & Pharmacy Resources.